Two doses of the Pfizer/BioNTech COVID-19 vaccine boosted protection against multi-system inflammatory syndrome (MIS-C) in adolescents aged between 12 and 18 years, suggests new research published in the Morbidity and Mortality Weekly Report.

The vaccine was found to be 91% effective in protecting fully vaccinated adolescents against MIS-C, noted researchers. Between July and mid-December 2021, when the Delta variant was dominating in the U.S., 102 patients across 20 states were hospitalized for MIS-C. Of these only 5% were vaccinated against COVID-19. None of the fully vaccinated patients with MIS-C needed respiratory or cardiovascular life support, while 39% of the unvaccinated MIS-C patients needed it.

A previous study in France had also shown that full vaccination could protect against the onset of MIS-C in adolescents… (Medpage Today)